TERT promoter mutations are one of the most potent prognostic biomarkers in thyroid cancer, and it is well known that coexistence of the TERT promoter and BRAFV600E mutation exerts synergistic effects leading to poor prognosis [1]. The gene discussed is TERT; the disease is thyroid gland carcinoma.